COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #137 of 231
9/21 Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Gentry et al., Lancet Rheumatology, doi:10.1016/S2665-9913(20)30305-2 (Peer Reviewed)
Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study
Source   PDF   Share   Tweet
Retrospective patients with rheumatologic conditions showing zero mortality with HCQ, odds ratio OR 0.13, p=0.10. 0 of 10,703 COVID-19 deaths for HCQ patients versus 7 of 21,406 for control patients.
COVID-19 cases OR 0.79, p=0.27. There are several significant differences in the propensity matched patients that could affect results, e.g., 20.9% SLE versus 24.7%.

Gentry et al., 9/21/2020, retrospective, database analysis, USA, North America, peer-reviewed, 6 authors.
risk of death, 86.7% lower, RR 0.13, p = 0.10, treatment 0 of 10703 (0.0%), control 7 of 21406 (0.0%), odds ratio converted to relative risk.
risk of COVID-19 case, 20.9% lower, RR 0.79, p = 0.27, odds ratio converted to relative risk.
Details of all 231 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit